Activity Overview
This online, on-demand virtual symposium brings together renowned experts in dry eye disease (DED). In this educational program, these experts use a case-based format to discuss the latest data regarding management of this disorder, share their perspectives and best practices, and forecast applications of key clinical challenges and questions regarding the diagnosis and treatment of DED and the updated report from the third Tear Film and Ocular Surface Society Dry Eye Workshop (TFOS DEWS III).
This educational activity is an archive of the live virtual symposium held on February 16, 2026.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, and other eyecare professionals involved in the management of patients with dry eye disease (DED).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the clinically relevant updates on the diagnosis and management of DED in the 2025 TFOS DEWS III reports
- Select appropriate diagnostic methods in the assessment of patients with DED to identify etiologic drivers
- Evaluate the mechanisms, safety, efficacy, and ease of use of current and novel therapies that address DED subtypes and etiologic factors
- Develop individualized treatment plans for optimal management of DED for cataract and refractive surgery patients
Rahul Tonk, MD
Associate
Professor of Clinical Ophthalmology
Medical
Director
Bascom Palmer
Eye Institute University of Miami Health System
The Lennar
Foundation Medical Center
Miami, FL
Disclosures: Consultant: AbbVie, Alcon, Bausch + Lomb, Dompé, Glaukos, Johnson & Johnson, Sight Sciences, Tarsus; Speaker: Dompé, Johnson & Johnson
Jade Coats, OD, FAAO
Optometrist
McDonald Eye
Associates
Bentonville,
AR
Disclosures: Advisory Board: AbbVie, Alcon, Bausch + Lomb, Dompé, Harrow, LENZ Therapeutics, Novaliq, Orasis Pharmaceuticals, Sun Pharmaceutical, Tarsus Pharmaceuticals, Tenpoint, Thea Pharma, Trukera Medical, Viatris, Zeiss; Speakers Bureau: Alcon, Bausch + Lomb, Dompé, Harrow, Orasis Pharmaceuticals, Sun Pharmaceutical, Tarsus Pharmaceuticals, Viatris
Aaleya Koreishi, MD
Founding
Partner
Cornea
Consultants of Texas
Fort Worth,
Arlington, Plano, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alcon, Bausch + Lomb, Dompé
Zeba Syed, MD
Director,
Cornea Fellowship Program
Wills Eye
Hospital
Philadelphia,
PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: BioLattice, BioTissue, Bruder, Dompé, Glaukos, Recordati, Sun, Tarsus
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
